A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.

[1]  D. Peabody,et al.  VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus , 2012, PloS one.

[2]  D. Lowy,et al.  Understanding and learning from the success of prophylactic human papillomavirus vaccines , 2012, Nature Reviews Microbiology.

[3]  R. Roden,et al.  Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate , 2012, PloS one.

[4]  A. Jegerlehner,et al.  Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.

[5]  Michael S. Goldberg,et al.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery , 2012, Proceedings of the National Academy of Sciences.

[6]  P. Naud,et al.  Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine , 2012, Human vaccines & immunotherapeutics.

[7]  L. Stevceva.  Toll-like receptor agonists as adjuvants for HIV vaccines. , 2011, Current medicinal chemistry.

[8]  D. Peabody,et al.  A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2 , 2011, PloS one.

[9]  J. Schiller,et al.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. , 2010, Vaccine.

[10]  R. Roden,et al.  Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines , 2009, Journal of Virology.

[11]  D. Lowy,et al.  Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines , 2009, Journal of the National Cancer Institute.

[12]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[13]  P. Stern,et al.  Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. , 2009, Vaccine.

[14]  D. Lowy,et al.  Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus , 2008, Journal of Virology.

[15]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[16]  J. Schiller,et al.  Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model1 , 2008, The Journal of Immunology.

[17]  H. Yoshikawa,et al.  Modification of human papillomavirus‐like particle vaccine by insertion of the cross‐reactive L2‐epitopes , 2008, Journal of medical virology.

[18]  R. Roden,et al.  Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2 , 2008, Proceedings of the National Academy of Sciences.

[19]  B. Trus,et al.  Arrangement of L2 within the Papillomavirus Capsid , 2008, Journal of Virology.

[20]  I. Bossis,et al.  A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2 , 2007, Journal of Virology.

[21]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[22]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[23]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[24]  J. Schiller,et al.  Chapter 17: Second generation HPV vaccines to prevent cervical cancer. , 2006, Vaccine.

[25]  S. Schwartz,et al.  Identification of Human Papillomavirus Type 16 L1 Surface Loops Required for Neutralization by Human Sera , 2006, Journal of Virology.

[26]  S. Akira,et al.  Papillomavirus Capsid Mutation To Escape Dendritic Cell-Dependent Innate Immunity in Cervical Cancer , 2005, Journal of Virology.

[27]  D. Lowy,et al.  Maturation of Papillomavirus Capsids , 2005, Journal of Virology.

[28]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[29]  Jacob M Hooker,et al.  Interior surface modification of bacteriophage MS2. , 2004, Journal of the American Chemical Society.

[30]  D. Lowy,et al.  Efficient Intracellular Assembly of Papillomaviral Vectors , 2004, Journal of Virology.

[31]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[32]  R. Karron,et al.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.

[33]  N. Christensen,et al.  The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. , 1991, Virology.

[34]  M. Pabst,et al.  Removal of endotoxin from protein solutions by phase separation using Triton X-114. , 1990, Journal of immunological methods.

[35]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.